` 2157 (Lepu Biopharma Co Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

L
2157
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, Lepu Biopharma Co Ltd has outperformed Hang Seng (Hong Kong), delivering a return of +26% compared to the Hang Seng (Hong Kong)'s +12% growth.

Stocks Performance
2157 vs Hang Seng (Hong Kong)

Loading
2157
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
2157 vs Hang Seng (Hong Kong)

Performance Gap Between 2157 and HSI
HIDDEN
Show

Performance By Year
2157 vs Hang Seng (Hong Kong)

Loading
2157
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Lepu Biopharma Co Ltd vs Peers

Hang Seng (Hong Kong)
2157
RYI
AVGR
BROG
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Lepu Biopharma Co Ltd
Glance View

Market Cap
7.5B HKD
Industry
Biotechnology

Lepu Biopharma Co., Ltd. operates as an an innovation-driven biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-02-23. The firm mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The firm's products are sold at home and abroad.

Lepu Biopharma Co Ltd Intrinsic Value
HIDDEN
Show
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett